The trial evaluates R3 Vascular’s next-generation drug-eluting bioresorbable scaffold, MAGNITUDE®, for below-the-knee (BTK) PAD, which according to the American Heart Association affects more than 200 million people globally, and 10 to 12 million in the U.S. older than the age of 40.  The most common type of PAD affects the lower-extremity where blood flow is reduced to the legs and feet.  Each year, approximately 150,000 leg amputations are performed in the U.S. alone.